[1] Nakanuma Y, Klimstra DS, Komuta M, et al. Intrahepatic cholangiocarcinoma. WHO Classification of tumours. of digestive system tumours. 5th edition, 2019:254-259.
[2] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int, 2019, 5:19-31.
[3] Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol, 2018,7:52.
[4] Theise ND,Nakashima O, Park YN, et al. Combined hepatocellular-cholangiocarcinoma. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. 4th edition.Geneva,2010:225-227.
[5] Hayashi A,?Misumi K, Shibahara J, et al. Distinct clinicopathologic and genetic features of 2 intrahepatic cholangiocarcinomas. Am J Surg Pathol, 2016, 40:1021-1030.
[6] 张永杰,丛文铭.胆道病理学.第一版.上海:上海科学技术出版社,2019:128.
[7] Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci, 2015, 22:94-100.
[8] Nakamuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.World J Hepatol, 2010, 2: 419-427.
[9] Nakamuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol, 2015, 29:277-293.
[10] Sigel CS, Drill E, Zhou Y, et al. Intrahepatic cholangiocarcinomas have histologically distinct small and large duct patterns. Am J Surg Pathol, 2018, 42: 1334-1345.
[11] Akita M, Fujikura K, Ajiki T, et al. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol, 2017,30:986-997.
[12] Aishima S, Kuroda Y, Nishihara Y, et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol, 2007,31:1059-1067.
[13] Rhee H, Ko JE, Chung BA,et al. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int, 2018, 38:113-124.
[14] Liau JY, Tsai JH, Yuan RH, et al. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol, 2014, 27:1163-1173.
[15] Arumugam T, Brandt W, Ramachandran V, et al. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas, 2011, 40:815-822.
[16] Komuta M, Govaere O,Vandecaveye V,et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology,2012,55:1876-1888.
[17] Kim SJ, Akita M, Sung YN, et al. MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations. Am J Surg Pathol, 2018, 42: 512-521.
[18] Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatolgy, 2014, 59: 1427-1434.
[19] Sasaki M, Sato Y, Nakanuma Y. Cholangiolocellular Carcinoma With “Ductal Plate Malformation” Pattern May Be Characterized by ARID1A Genetic Alterations. Am J Surg Pathol, 2019, 43:352-360.
[20] Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology, 2018, 68:113-126.
[21] Sempoux C, Fan C, Singh p, et al. Cholangiocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis, 2011, 31:104-110.
[22] Kozaka K, Sasaki M, Fujii T, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma'. Histopathology, 2007, 51:390-400.
[23] Wang HL, Kim CJ, Koo J, et al. Practical immunohistochemistry in neoplastic pathology of the gastrointestinal tract, liver, biliary tract, and pancreas. Arch Pathol Lab Med, 2017, 141:1155-1180.
[24] Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep, 2017, 19:2878-2880.
[25] Balitzer D,Joseph NM,Ferrell L, et al. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Mod pathol, 2019, 32:1486-1494. |
